Race against time: can new Alzheimer's drug delay need for care?
NCT ID NCT06566170
Summary
This large, real-world study aims to see if adding the drug donanemab to usual care helps people with early Alzheimer's disease maintain their independence longer than usual care alone. It will follow about 6,250 participants for over five years, tracking how long they can live at home without needing significantly more help. The main goal is to measure if the drug slows the progression to greater dependence on caregivers or moving to a care facility.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rehabilitation & Neurological Services
RECRUITINGHuntsville, Alabama, 35805-4046, United States
Contact
Conditions
Explore the condition pages connected to this study.